nach oben

Erschienen in:

01.05.2004 | Case Report

Toxic Epidermal Necrolysis Induced by a Triple-Drug Regimen for Helicobacter Pylori Eradication

verfasst von: Dr Yoshihiro Matsukawa, Hiroyuki Hara, Masanori Aoki, Kentaro Inada, Motohide Kaneko, Ko Mitamura, Umihiko Sawada, Shigemasa Sawada, Takashi Horie, Toyoko Ochiai

Erschienen in: Clinical Drug Investigation | Ausgabe 5/2004

Einloggen, um Zugang zu erhalten

Excerpt

Helicobacter pylori is known to cause peptic ulcer, gastritis, gastric cancer and mucosa-associated lymphoid tissue lymphoma (MALToma). In addition, it appears to influence the course of various diseases.[1‐13] Therefore, use of therapy to eradicate this pathogen is becoming increasingly common throughout the world. Almost all medical strategies for eradication of H. pylori require three drugs: a proton-pump inhibitor (PPI) and two antibiotics, i.e. triple therapy. …

Gasbarrini A, De Luca A, Fiore G, et al. Beneficial effects of Helicobacter pylori eradication on migraine. Hepatogastroenterology 1998; 48: 765–70

Zentilin P, Savarino V, Garnero A, et al. Is Helicobacter pylori infection a risk factor for disease severity in rheumatoid arthritis? Gastroenterology 1999; 116: 503–4PubMedCrossRef

Seriolo B, Cutolo M, Zentilin P, et al. Helicobacter pylori infection in rheumatoid arthritis. J Rheumatol 2001; 28: 1195–6PubMed

Aragona P, Magazzu G, Macchia G, et al. Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren’s syndrome. J Rheumatol 1999; 26: 1306–11PubMed

Melby KK, Kvien TK, Glennas A. Helicobacter pylori — a trigger of reactive arthritis? Infection 1999; 27: 252–5PubMedCrossRef

Razavi B. Reactive arthritis after Helicobacter pylori eradication. Lancet 2000; 355: 720PubMedCrossRef

Ridker PM, Hennekens GH, Buring JE, et al. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, Herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131: 573–7PubMed

Gasbarrini A, Franceschi F, Tartaglionse R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1999; 352: 878CrossRef

Radenhausen M, Schulzke JP, Geilen CC, et al. Frequent presence of Helicobacter pylori in chronic urticaria. Acta Derm Venereol 2000; 80: 48–9PubMedCrossRef

10.

Farkas H, Fust G, Fekete B, et al. Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema. Lancet 2001; 358: 1695–6PubMedCrossRef

11.

Cicconi V, Carloni E, Franceschi F, et al. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am J Med 2001; 111: 163–4PubMedCrossRef

12.

Kountouras J, Mylopoulos N, Chatzopoulos D, et al. Eradication of Helicobacter pylori may be beneficial in the treatment of chronic open-angle glaucoma. Arch Intern Med 2002; 162: 1237–44PubMedCrossRef

13.

Salimi-Khayati A, Sharami H, Mansour-Ghanaei F, et al. Helicobacter pylori seropositivity and the incidence of hyperemesis gravidarum. Med Sci Monit 2003; 9: CR12–5PubMed

14.

Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 2000; 136: 323–7PubMedCrossRef

15.

Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18: 485–95PubMed

16.

Paquet P, Arrese JE, Beguin Y, et al. Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell’s syndrome) and acute graft-versus-host reaction. Curr Top Pathol 2001; 94: 49–63PubMedCrossRef

17.

Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Arch Dermatol 1993; 129: 466–8PubMedCrossRef

18.

Paquet P, Nikkeis A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 30: 605–8CrossRef

19.

Rzany B, Schmitt H, Schopf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol 1991; 71: 171–2PubMed

20.

Cox NH. Acute disseminated epidermal necrosis due to omeprazole. Lancet 1992; 340: 857PubMedCrossRef

21.

Miyata T, Yaguchi A, Hashimoto A, et al. Toxic epidermal necrolysis due to omeprazole [in Japanese, abstract in English]. Nishinihon J Dermatol 1996; 58: 574–7CrossRef

22.

Cattelan AM, Trevenzoli M, Sasset L, et al. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of literature. J Infect 2001; 43: 246–54PubMedCrossRef

23.

Masia M, Gutierrez F, Jimeno A, et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med 2002; 162: 474–6PubMedCrossRef

Titel: Toxic Epidermal Necrolysis Induced by a Triple-Drug Regimen for Helicobacter Pylori Eradication
verfasst von: Dr Yoshihiro Matsukawa
Hiroyuki Hara
Masanori Aoki
Kentaro Inada
Motohide Kaneko
Ko Mitamura
Umihiko Sawada
Shigemasa Sawada
Takashi Horie
Toyoko Ochiai
Publikationsdatum: 01.05.2004
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 5/2004
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.2165/00044011-200424050-00007

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2004

Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder

Effect of Betamethasone-Loratadine Combination Therapy on Severe Exacerbations of Allergic Rhinitis

Risk Reduction Strategies in Ischaemic Stroke

Weight Gain, Improvements in Metabolic Profiles and Immunogenicity with Insulin or Sulphonylurea Administration in AIDS

Cost of Heart Failure in Patients Receiving β-Blockers and Angiotensin-Converting Enzyme Inhibitors

Switch from Risperidone to Perospirone in Patients with Chronic Schizophrenia